Cellvation, Inc. (“Cellvation”), a portfolio company of Fortress Biotech, is focused on the development and commercialization of novel cellular therapies for the treatment of traumatic brain injury (TBI). We aim to: (1) secure rights to new technologies via acquisition, licensing, co-development and/or other partnering; (2) fund research and development of new technologies; and (3) ultimately introduce new technologies to market. In November 2016, Cellvation, Inc. was formed to develop novel cellular therapies for the treatment of severe traumatic brain injury (TBI). Pursuant to a license agreement with The University of Texas, Health Science Center at Houston, Texas, Cellvation secured exclusive worldwide rights to technologies, including the clinical trial protocols and approaches for the use of CEVA-102 to treat severe TBI as well as a novel bioreactor to up-regulate anti-inflammatory gene programs using mechanotransductive shear stress culture conditions.
TBI is a major public health problem, as it is a contributing factor to about a third of the injury-related deaths in the US. To-date, no product for the treatment of severe TBI has received FDA regulatory approval while decades of well-designed clinical trials have failed to demonstrate clinically meaningful outcomes in patients, despite ongoing findings and reports of promising therapies and treatments in animal models.
Cellvation is headquartered in New York City.
Contact Information
Cellvation, Inc.
2 Gansevoort Street
9th Floor
New York, NY 10014
info@cellvation.com
Investor Relations
Frank Taffy, Board Member
ir@cellvation.com